Similarly, in two mouse PCOS models, GLP-1 agonist-based therapies outperformed metformin at enhancing insulin sensitivity and lowering fasting insulin levels (Sánchez-Garrido et al. 2024). This evidence concerns the gene GLP1R and polycystic ovary syndrome.